Eyelid and Conjunctival Neoplasms

  • Lilly Droll
  • Aaron Savar
  • Bita EsmaeliEmail author


The spectrum of neoplasms that can affect the eyelids and conjunctiva is vast. In this chapter, we review the epidemiology, clinical features, pathology, and management of these lesions. Basal cell carcinoma is the most common eyelid malignancy. Excision is the mainstay of treatment for this tumor that rarely metastasizes. Squamous cell carcinoma is the second most common eyelid malignancy. It has a higher risk of nodal and systemic metastasis. A high index of suspicion is necessary for sebaceous carcinoma as it can appear similar to other conditions. Cutaneous melanoma of the eyelid has a propensity for nodal and systemic metastasis. Although local excision is central to the management, frozen sections are not adequate for control of the margins. Numerous other tumors can affect the eyelids, including sweat gland tumors, Merkel cell carcinoma, vascular tumors, lymphoma, and metastatic tumors. Conjunctival melanoma is rare but potentially lethal. Excision is usually accompanied by adjuvant treatments, such as cryotherapy and topical chemotherapy. Squamous conjunctival lesions include both benign and malignant lesions. Human papillomavirus and human immunodeficiency virus have been associated with these lesions.


Squamous Cell Carcinoma Basal Cell Carcinoma Perineural Invasion Merkel Cell Carcinoma Sebaceous Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Deprez M, Uffer S. Clinicopathological features of eyelid skin tumors. A retrospective study of 5504 cases and review of literature. Am J Dermatopathol. 2009;31(3):256–62. doi:210.1097/DAD.1090b1013e3181961861.PubMedGoogle Scholar
  2. 2.
    Cook Jr BE, Bartley GB. Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmsted County, Minnesota. Ophthalmology. 1999;106(4):746–50.PubMedGoogle Scholar
  3. 3.
    Bielsa I, Soria X, Esteve M, Ferrandiz C. Population-based incidence of basal cell carcinoma in a Spanish Mediterranean area. Br J Dermatol. 2009;161(6):1341–6.PubMedGoogle Scholar
  4. 4.
    Dallas RE, Anne K, Peter JH, Peter LR, Michael GW, Bruce KA. Incidence of non-melanocytic skin cancer in Geraldton, Western Australia. Int J Cancer. 1997;73(5):629–33.Google Scholar
  5. 5.
    Malhotra R, Huilgol SC, Huynh NT, Selva D. The Australian Mohs database, part I: periocular basal cell carcinoma experience over 7 years. Ophthalmology. 2004;111(4):624–30.PubMedGoogle Scholar
  6. 6.
    Nemet AY, Deckel Y, Martin PA, Kourt G, Chilov M, Sharma V, et al. Management of periocular basal and squamous cell carcinoma: a series of 485 cases. Am J Ophthalmol. 2006;142(2):293–7.PubMedGoogle Scholar
  7. 7.
    Zanetti R, Rosso S, Martinez C, Navarro C, Schraub S, Sancho-Garnier H, et al. The multicentre south European Study ‘Helios’. I: skin characteristics and sunburns in basal cell and squamous cell carcinomas of the skin. Br J Cancer. 1996;73(11):1440–6.PubMedCentralPubMedGoogle Scholar
  8. 8.
    Honavar SG, Shields JA, Shields CL, Eagle Jr RC, Demirci H, Mahmood EZ. Basal cell carcinoma of the eyelid associated with Gorlin-Goltz syndrome. Ophthalmology. 2001;108(6):1115–23.PubMedGoogle Scholar
  9. 9.
    Malhotra AK, Somesh G, Binod KK, Kaushal KV. Multiple basal cell carcinomas in xeroderma pigmentosum treated with imiquimod 5% cream. Pediatr Dermatol. 2008;25(4):488–91.PubMedGoogle Scholar
  10. 10.
    Batra RS, Larisa CK. A risk scale for predicting extensive subclinical spread of nonmelanoma skin cancer. Dermatol Surg. 2002;28(2):107–12.PubMedGoogle Scholar
  11. 11.
    Auw-Haedrich C, Frick S, Boehringer D, Mittelviefhaus H. Histologic safety margin in basal cell carcinoma of the eyelid: correlation with recurrence rate. Ophthalmology. 2009;116(4):802–6.PubMedGoogle Scholar
  12. 12.
    Smeets NWJ, Kuijpers DIM, Nelemans P, Ostertag JU, Verhaegh MEJM, Krekels GAM, et al. Mohs’ micrographic surgery for treatment of basal cell carcinoma of the face–results of a retrospective study and review of the literature. Br J Dermatol. 2004;151(1):141–7.PubMedGoogle Scholar
  13. 13.
    Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R. Basal cell carcinoma treated with Mohs surgery in Australia III. Perineural invasion. J Am Acad Dermatol. 2005;53(3):458–63.PubMedGoogle Scholar
  14. 14.
    Wong VA, Marshall JA, Whitehead KJ, Williamson RM, Sullivan TJ. Management of periocular basal cell carcinoma with modified En face frozen section controlled excision. Ophthal Plast Reconstr Surg. 2002;18(6):430–5.PubMedGoogle Scholar
  15. 15.
    Ramzi SC. Metastasizing basal cell carcinomas. Cancer. 1961;14(5):1036–40.Google Scholar
  16. 16.
    von Domarus H, Stevens PJ. Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature. J Am Acad Dermatol. 1984;10(6):1043–60.Google Scholar
  17. 17.
    Robert II CGM, Michael JE, Thomas GC, Catherine LS, Kelly MM. Basosquamous carcinoma. Cancer. 2000;88(6):1365–9.Google Scholar
  18. 18.
    Evan RF, Elson BH. Metastatic basal cell carcinoma: a clinicopathologic study of seventeen cases. Cancer. 1980;46(4):748–57.Google Scholar
  19. 19.
    McCord MW, Mendenhall WM, Parsons JT, Amdur RJ, Stringer SP, Cassisi NJ, et al. Skin cancer of the head and neck with clinical perineural invasion. Int J Radiat Oncol Biol Phys. 2000;47(1):89–93.PubMedGoogle Scholar
  20. 20.
    Leibovitch I, McNab A, Sullivan T, Davis G, Selva D. Orbital invasion by periocular basal cell carcinoma. Ophthalmology. 2005;112(4):717–23.PubMedGoogle Scholar
  21. 21.
    Conway RM, Themel S, Holbach LM. Surgery for primary basal cell carcinoma including the eyelid margins with intraoperative frozen section control: comparative interventional study with a minimum clinical follow up of 5 years. Br J Ophthalmol. 2004;88(2):236–8.PubMedCentralPubMedGoogle Scholar
  22. 22.
    Erika LS, Robert JA, William MM, Christopher GM, Jessica MK, Franklin F. Radiotherapy for basal cell carcinoma of the medial canthus region. Laryngoscope. 2009;119(12):2366–8.Google Scholar
  23. 23.
    Rhodes LE, de Rie MA, Leifsdottir R, Yu RC, Bachmann I, Goulden V, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy Vs surgery for nodular basal cell carcinoma. Arch Dermatol. 2007;143(9):1131–6.PubMedGoogle Scholar
  24. 24.
    Ll J, Kai K, Hannu U, Matti K. Imiquimod in the treatment of eyelid basal cell carcinoma. Acta Ophthalmol Scand. 2007;85(5):566–8.Google Scholar
  25. 25.
    Gallagher RP, Hill GB, Bajdik CD, Coldman AJ, Fincham S, McLean DI, et al. Sunlight exposure, pigmentation factors, and risk of nonmelanocytic skin cancer. II. Squamous cell carcinoma. Arch Dermatol. 1995;131(2):164–9.PubMedGoogle Scholar
  26. 26.
    Maurice EA, Ogbu N, Godwin E, Ekpo EB. Skin cancers amongst four Nigerian albinos. Int J Dermatol. 2009;48(6):636–8.Google Scholar
  27. 27.
    Herman S, Rogers HD, Ratner D. Immunosuppression and squamous cell carcinoma: a focus on solid organ transplant. Skinmed. 2007;6(5):234–8.PubMedGoogle Scholar
  28. 28.
    Röwert-Huber J, Patel MJ, Forschner T, Ulrich C, Eberle J, Kerl H, et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol. 2007;156(Suppl3):8–12.PubMedGoogle Scholar
  29. 29.
    Cassarino DS, Derienzo DP, Barr RJ. Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification–part two. J Cutan Pathol. 2006;33(4):261–79.PubMedGoogle Scholar
  30. 30.
    Lohmann CM, Solomon AR. Clinicopathologic variants of cutaneous squamous cell carcinoma. Adv Anat Pathol. 2001;8(1):27–36.PubMedGoogle Scholar
  31. 31.
    Faustina M, Diba R, Ahmadi MA, Esmaeli B. Patterns of regional and distant metastasis in patients with eyelid and periocular squamous cell carcinoma. Ophthalmology. 2004;111(10):1930–2.PubMedGoogle Scholar
  32. 32.
    Rowe DE, Carroll RJ, Day Jr CL. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. 1992;26(6):976–90.PubMedGoogle Scholar
  33. 33.
    Malhotra R, Huilgol SC, Huynh NT, Selva D. The Australian Mohs database: periocular squamous cell carcinoma. Ophthalmology. 2004;111(4):617–23.PubMedGoogle Scholar
  34. 34.
    Donaldson MJ, Sullivan TJ, Whitehead KJ, Williamson RM. Squamous cell carcinoma of the eyelids. Br J Ophthalmol. 2002;86(10):1161–5.PubMedCentralPubMedGoogle Scholar
  35. 35.
    Bowyer JD, Sullivan TJ, Whitehead KJ, Kelly LE, Allison RW. The management of perineural spread of squamous cell carcinoma to the ocular adnexae. Ophthal Plast Reconstr Surg. 2003;19(4):275–81.PubMedGoogle Scholar
  36. 36.
    Cook Jr BE, Bartley GB. Treatment options and future prospects for the management of eyelid malignancies: an evidence-based update. Ophthalmology. 2001;108(11):2099–100.Google Scholar
  37. 37.
    Petsuksiri J, Frank SJ, Garden AS, Ang KK, Morrison WH, Chao KSC, et al. Outcomes after radiotherapy for squamous cell carcinoma of the eyelid. Cancer. 2008;112(1):111–8.PubMedGoogle Scholar
  38. 38.
    Russell WH, Daniel JI, Robert JA, Christopher GM, John WW, Mikhail V, et al. Cutaneous squamous cell carcinoma metastatic to parotid-area lymph nodes. Laryngoscope. 2008;118(11):1989–96.Google Scholar
  39. 39.
    Phan R, Phan L, Ginsberg LE, Blumenschein G, Williams MD, Esmaeli B. Durable response to chemotherapy for recurrent squamous cell carcinoma of the cheek with perineural spread. Arch Ophthalmol. 2009;127(8):1074–5.PubMedGoogle Scholar
  40. 40.
    Shin DM, Glisson BS, Khuri FR, Ginsberg L, Papadimitrakopoulou V, Lee JJ, et al. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998;16(4):1325–30.PubMedGoogle Scholar
  41. 41.
    Rahman I, Maino A, Cook AE, Leatherbarrow B. Mortality following exenteration for malignant tumours of the orbit. Br J Ophthalmol. 2005;89(11):1445–8.PubMedCentralPubMedGoogle Scholar
  42. 42.
    Fitzpatrick PJ, Thompson GA, Easterbrook WM, Gallie BL, Payne DG. Basal and squamous cell carcinoma of the eyelids and their treatment by radiotherapy. Int J Radiat Oncol Biol Phys. 1984;10(4):449–54.PubMedGoogle Scholar
  43. 43.
    Calista D, Riccioni L, Coccia L. Successful treatment of squamous cell carcinoma of the lower eyelid with intralesional cidofovir. Br J Ophthalmol. 2002;86(8):932–3.PubMedCentralPubMedGoogle Scholar
  44. 44.
    Calzavara-Pinton PG, Venturini M, Sala R, Capezzera R, Parrinello G, Specchia C, et al. Methylaminolaevulinate-based photodynamic therapy of Bowen’s disease and squamous cell carcinoma. Br J Dermatol. 2008;159(1):137–44.PubMedGoogle Scholar
  45. 45.
    David BR, Elson BH. Cutaneous sebaceous neoplasms. Cancer. 1974;33(1):82–102.Google Scholar
  46. 46.
    Rao NA, Hidayat AA, McLean IW, Zimmerman LE. Sebaceous carcinomas of the ocular adnexa: a clinicopathologic study of 104 cases, with five-year follow-up data. Hum Pathol. 1982;13(2):113–22.PubMedGoogle Scholar
  47. 47.
    Song A, Carter KD, Syed NA, Song J, Nerad JA. Sebaceous cell carcinoma of the ocular adnexa: clinical presentations, histopathology, and outcomes. Ophthal Plast Reconstr Surg. 2008;24(3):194–200.PubMedGoogle Scholar
  48. 48.
    Shields JA, Demirci H, Marr BP, Eagle Jr RC, Shields CL. Sebaceous carcinoma of the eyelids: personal experience with 60 cases. Ophthalmology. 2004;111(12):2151–7.PubMedGoogle Scholar
  49. 49.
    Boniuk M, Zimmermann LE. Sebaceous carcinoma of the eyelid, eyebrow, caruncle and orbit. Int Ophthalmol Clin. 1972;12(1):225–57.PubMedGoogle Scholar
  50. 50.
    Takamura H, Yamashita H. Clinicopathological analysis of malignant eyelid tumor cases at Yamagata university hospital: statistical comparison of tumor incidence in Japan and in other countries. Jpn J Ophthalmol. 2005;49(5):349–54.PubMedGoogle Scholar
  51. 51.
    Tina D, Lynn DW, James BY. A retrospective review of 1349 cases of sebaceous carcinoma. Cancer. 2009;115(1):158–65.Google Scholar
  52. 52.
    Muqit MM, Roberts F, Lee WR, Kemp E. Improved survival rates in sebaceous carcinoma of the eyelid. Eye (Lond). 2004;18(1):49–53.Google Scholar
  53. 53.
    Richard PH, William JL, William HS, Edward GB, Jonathan JD, Gordon KK, et al. Sebaceous gland carcinoma: a subtle second malignancy following radiation therapy in patients with bilateral retinoblastoma. Cancer. 1998;83(4):767–71.Google Scholar
  54. 54.
    Rumelt S, Hogan NR, Rubin PA, Jakobiec FA. Four-eyelid sebaceous cell carcinoma following irradiation. Arch Ophthalmol. 1998;116(12):1670–2.PubMedGoogle Scholar
  55. 55.
    Rishi K, Font RL. Sebaceous gland tumors of the eyelids and conjunctiva in the Muir-Torre syndrome: a clinicopathologic study of five cases and literature review. Ophthal Plast Reconstr Surg. 2004;20(1):31–6.PubMedGoogle Scholar
  56. 56.
    Tan KC, Lee ST, Cheah ST. Surgical treatment of sebaceous carcinoma of eyelids with clinico-pathological correlation. Br J Plast Surg. 1991;44(2):117–21.PubMedGoogle Scholar
  57. 57.
    Doxanas MT, Green WR. Sebaceous gland carcinoma: review of 40 cases. Arch Ophthalmol. 1984;102(2):245–9.PubMedGoogle Scholar
  58. 58.
    Miki I, Kiyoshi M, Takeshi N, Jun M, Keiichi I, Cheng-Sheng C, et al. Sebaceous carcinoma of the eyelids: thirty cases from Japan. Pathol Int. 2008;58(8):483–8.Google Scholar
  59. 59.
    Ho VH, Ross MI, Prieto VG, Khaleeq A, Kim S, Esmaeli B. Sentinel lymph node biopsy for sebaceous cell carcinoma and melanoma of the ocular adnexa. Arch Otolaryngol Head Neck Surg. 2007;133(8):820–6.PubMedGoogle Scholar
  60. 60.
    Husain A, Blumenschein G, Esmaeli B. Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid. Int J Dermatol. 2008;47(3):276–9.PubMedGoogle Scholar
  61. 61.
    Savar A, Oellers P, Myers J, Prieto VG, Ivan D, Esameli B. Positive sentinel node in sebaceous carcinoma of the eyelid. Ophthal Plast Reconstr Surg. 2011;27(1):e4–6.PubMedGoogle Scholar
  62. 62.
    Chao AN, Shields CL, Krema H, Shields JA. Outcome of patients with periocular sebaceous gland carcinoma with and without conjunctival intraepithelial invasion. Ophthalmology. 2001;108(10):1877–83.PubMedGoogle Scholar
  63. 63.
    Spencer JM, Nossa R, Tse DT, Sequeira M. Sebaceous carcinoma of the eyelid treated with Mohs micrographic surgery. J Am Acad Dermatol. 2001;44(6):1004–9.PubMedGoogle Scholar
  64. 64.
    Folberg R, Whitaker DC, Tse DT, Nerad JA. Recurrent and residual sebaceous carcinoma after Mohs’ excision of the primary lesion. Am J Ophthalmol. 1987;103(6):817–23.PubMedGoogle Scholar
  65. 65.
    Shields JA, Demirci H, Marr BP, Eagle Jr RC, Stefanyszyn M, Shields CL. Conjunctival epithelial involvement by eyelid sebaceous carcinoma. The 2003 J. Howard stokes lecture. Ophthal Plast Reconstr Surg. 2005;21(2):92–6.PubMedGoogle Scholar
  66. 66.
    Adam KR, James SM. Mitomycin-C as adjuvant therapy in the treatment of sebaceous gland carcinoma in high-risk locations. Clin Experiment Ophthalmol. 2009;37(4):352–6.Google Scholar
  67. 67.
    Yen MT, Tse DT, Wu X, Wolfson AH. Radiation therapy for local control of eyelid sebaceous cell carcinoma: report of two cases and review of the literature. Ophthal Plast Reconstr Surg. 2000;16(3):211–5.PubMedGoogle Scholar
  68. 68.
    Hoersch B, Leiter U, Garbe C. Is head and neck melanoma a distinct entity? A clinical registry-based comparative study in 5702 patients with melanoma. Br J Dermatol. 2006;155(4):771–7.PubMedGoogle Scholar
  69. 69.
    Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, Edwards BK (eds) Seer cancer statistics review. Bethesda, 2010. Accessed 25 Feb 2010 based on November 2008 SEER data submission, posted to the SEER web site (2009).
  70. 70.
    Marrett LD, King WD, Walter SD, From L. Use of host factors to identify people at high risk for cutaneous malignant melanoma. CMAJ. 1992;147(4):445–53.PubMedCentralPubMedGoogle Scholar
  71. 71.
    Kennedy C, Bajdik CD, Willemze R, De Gruijl FR, Bouwes Bavinck JN. The influence of painful sunburns and lifetime Sun exposure on the risk of actinic keratoses, seborrheic warts, melanocytic nevi, atypical nevi, and skin cancer. J Invest Dermatol. 2003;120(6):1087–93.PubMedGoogle Scholar
  72. 72.
    Yu GP, Hu DM, McCormick SA. Latitude and incidence of ocular melanoma. Photochem Photobiol. 2006;82(6):1621–6.PubMedGoogle Scholar
  73. 73.
    Tsai T, Vu C, Henson DE. Cutaneous, ocular and visceral melanoma in African Americans and Caucasians. Melanoma Res. 2005;15(3):213–7.PubMedGoogle Scholar
  74. 74.
    Newnham A, Moller H. Trends in the incidence of cutaneous malignant melanomas in the south east of England, 1960–1998. J Public Health. 2002;24(4):268–75.Google Scholar
  75. 75.
    William T, Kara S, Natalie NC, Michael P, Hobart WW. Tanning Bed exposure increases the risk of malignant melanoma. Int J Dermatol. 2007;46(12):1253–7.Google Scholar
  76. 76.
    Wang Y, Digiovanna JJ, Stern JB, Hornyak TJ, Raffeld M, Khan SG, et al. Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas. Proc Natl Acad Sci USA. 2009;106(15):6279–84.PubMedCentralPubMedGoogle Scholar
  77. 77.
    Margo CE, Duncan WC, Rich A, Garcia E, Stricker J. Periocular cutaneous melanoma arising in a radiotherapy field. Ophthal Plast Reconstr Surg. 2004;20(4):319–20.PubMedGoogle Scholar
  78. 78.
    Fortes C, Mastroeni S, Melchi F, Pilla MA, Alotto M, Antonelli G, et al. The association between residential pesticide use and cutaneous melanoma. Eur J Cancer. 2007;43(6):1066–75.PubMedGoogle Scholar
  79. 79.
    Sanchez R, Ivan D, Esmaeli B. Eyelid and periorbital cutaneous malignant melanoma. Int Ophthalmol Clin. 2009;49(4):25–43.PubMedGoogle Scholar
  80. 80.
    Esmaeli B, Wang B, Deavers M, Gillenwater A, Goepfert H, Diaz E, et al. Prognostic factors for survival in malignant melanoma of the eyelid skin. Ophthal Plast Reconstr Surg. 2000;16(4):250–7.PubMedGoogle Scholar
  81. 81.
    Golger A, Young DS, Ghazarian D, Neligan PC. Epidemiological features and prognostic factors of cutaneous head and neck melanoma: a population-based study. Arch Otolaryngol Head Neck Surg. 2007;133(5):442–7.PubMedGoogle Scholar
  82. 82.
    Nagore E, Oliver V, Botella-Estrada R, Moreno-Picot S, Insa A, Fortea JM. Prognostic factors in localized invasive cutaneous melanoma: high value of mitotic rate, vascular invasion and microscopic satellitosis. Melanoma Res. 2005;15(3):169–77.PubMedGoogle Scholar
  83. 83.
    Savar A, Ross MI, Prieto VG, Ivan D, Kim S, Esmaeli B. Sentinel lymph node biopsy for ocular adnexal melanoma: experience in 30 patients. Ophthalmology. 2009;116(11):2217–23.PubMedGoogle Scholar
  84. 84.
    Chan FM, O’Donnel BA, Whitehead K, Ryman W, Sullivan TJ. Treatment and outcomes of malignant melanoma of the eyelid: a review of 29 cases in Australia. Ophthalmology. 2007;114(1):187–92.PubMedGoogle Scholar
  85. 85.
    Michael MW, Arthur JS, Thomas BF, Martin CM, Alfred WK, Wallace HC, et al. Clinical characteristics of early cutaneous melanoma. Cancer. 1980;45(10):2684–6.Google Scholar
  86. 86.
    Kittler H, Seltenheim M, Dawid M, Pehamberger H, Wolff K, Binder M. Morphologic changes of pigmented skin lesions: a useful extension of the ABCD rule for dermatoscopy. J Am Acad Dermatol. 1999;40(4):558–62.PubMedGoogle Scholar
  87. 87.
    Vaziri M, Buffam FV, Martinka M, Oryschak A, Dhaliwal H, White VA. Clinicopathologic features and behavior of cutaneous eyelid melanoma. Ophthalmology. 2002;109(5):901–8.PubMedGoogle Scholar
  88. 88.
    Lessner A, Sexton M, Margo CE. Amelanotic malignant melanoma of the eyelid. Arch Ophthalmol. 1991;109(8):1166–7.PubMedGoogle Scholar
  89. 89.
    Gualandri L, Betti R, Crosti C. Clinical features of 36 cases of amelanotic melanomas and considerations about the relationship between histologic subtypes and diagnostic delay. J Eur Acad Dermatol Venereol. 2009;23(3):283–7.PubMedGoogle Scholar
  90. 90.
    Gündüz K, Shields JA, Shields CL, Eagle Jr RC. Periorbital cellular blue nevus leading to orbitopalpebral and intracranial melanoma. Ophthalmology. 1998;105(11):2046–50.PubMedGoogle Scholar
  91. 91.
    Patel BC, Egan CA, Lucius RW, Gerwels JW, Mamalis N, Anderson RL. Cutaneous malignant melanoma and oculodermal melanocytosis (nevus of Ota): report of a case and review of the literature. J Am Acad Dermatol. 1998;38(5 Pt 2):862–5.PubMedGoogle Scholar
  92. 92.
    Sober AJ, Chuang TY, Duvic M, Farmer ER, Grichnik JM, Halpern AC, et al. Guidelines/outcomes committee: guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol. 2001;45(4):579–86.PubMedGoogle Scholar
  93. 93.
    Esmaeli B, Youssef A, Naderi A, Ahmadi MA, Meyer DR, McNab A. Margins of excision for cutaneous melanoma of the eyelid skin: the collaborative eyelid skin melanoma group report. Ophthal Plast Reconstr Surg. 2003;19(2):96–101.PubMedGoogle Scholar
  94. 94.
    Then SY, Malhotra R, Barlow R, Kurwa H, Huilgol S, Joshi N, et al. Early cure rates with narrow-margin slow-mohs surgery for periocular malignant melanoma. Dermatol Surg. 2009;35(1):17–23.PubMedGoogle Scholar
  95. 95.
    Prieto VG, Argenyi ZB, Barnhill RL, Duray PH, Elenitsas R, From L, et al. Are En face frozen sections accurate for diagnosing margin status in melanocytic lesions? Am J Clin Pathol. 2003;120(2):203–8.PubMedGoogle Scholar
  96. 96.
    Shumaker PR, Kelley B, Swann MH, Greenway HT. Modified Mohs micrographic surgery for periocular melanoma and melanoma in situ: long-term experience at Scripps clinic. Dermatol Surg. 2009;35(8):1263–70.PubMedGoogle Scholar
  97. 97.
    Menaker GM, Chiang JK, Tabila B, Moy RL. Rapid Hmb-45 staining in Mohs micrographic surgery for melanoma in situ and invasive melanoma. J Am Acad Dermatol. 2001;44(5):833–6.PubMedGoogle Scholar
  98. 98.
    Stannard CE, Sealy GR, Hering ER, Pereira SB, Knowles R, Hill JC. Malignant melanoma of the eyelid and palpebral conjunctiva treated with iodine-125 brachytherapy. Ophthalmology. 2000;107(5):951–8.PubMedGoogle Scholar
  99. 99.
    Masayuki S, Kohji T, Hidehiko Y, Airo T, Yasuaki N, Kazuo N. Apocrine adenocarcinoma of the eyelid with aggressive biological behavior: report of a case. Pathol Int. 2002;52(2):169–73.Google Scholar
  100. 100.
    Hoppenreijs VPT, Reuser TTQ, Mooy CM, de Keizer RJW, Mourits MP. Syringomatous carcinoma of the eyelid and orbit: a clinical and histopathological challenge. Br J Ophthalmol. 1997;81(8):668–72.PubMedCentralPubMedGoogle Scholar
  101. 101.
    John DW, Ramon LF. Mucinous sweat gland adenocarcinoma of eyelid. A clinicopathologic study of 21 cases with histochemical and electron microscopic observations. Cancer. 1979;44(5):1757–68.Google Scholar
  102. 102.
    Duffy MT, Harrison W, Sassoon J, Hornblass A. Sclerosing sweat duct carcinoma of the eyelid margin: unusual presentation of a rare tumor. Ophthalmology. 1999;106(4):751–6.PubMedGoogle Scholar
  103. 103.
    Durairaj VD, Hink EM, Kahook MY, Hawes MJ, Paniker PU, Esmaeli B. Mucinous eccrine adenocarcinoma of the periocular region. Ophthal Plast Reconstr Surg. 2006;22(1):30–5.PubMedGoogle Scholar
  104. 104.
    Wollensak G, Witschel H, Böhm N. Signet ring cell carcinoma of the eccrine sweat glands in the eyelid. Ophthalmology. 1996;103(11):1788–93.PubMedGoogle Scholar
  105. 105.
    Auw-Haedrich C, Boehm N, Weissenberger C. Signet ring carcinoma of the eccrine sweat gland in the eyelid, treated by radiotherapy alone. Br J Ophthalmol. 2001;85(1):112–3.PubMedGoogle Scholar
  106. 106.
    Agelli M, Clegg LX. Epidemiology of primary Merkel cell carcinoma in the united states. J Am Acad Dermatol. 2003;49(5):832–41.PubMedGoogle Scholar
  107. 107.
    Miller RW, Rabkin CS. Merkel cell carcinoma and melanoma: etiological similarities and differences. Cancer Epidemiol Biomarkers Prev. 1999;8(2):153–8.PubMedGoogle Scholar
  108. 108.
    Buell JF, Trofe J, Hanaway MJ, Beebe TM, Gross TG, Alloway RR, et al. Immunosuppression and Merkel cell cancer. Transplant Proc. 2002;34(5):1780–1.PubMedGoogle Scholar
  109. 109.
    Rawlings NG, Brownstein S, Jordan DR. Merkel cell carcinoma masquerading as chalazion. Can J Ophthalmol. 2007;24(3):469–70.Google Scholar
  110. 110.
    Andea AA, Coit DG, Amin B, Busam KJ. Merkel cell carcinoma: histopathologic features and prognosis. Cancer. 2008;113(9):2549–58.PubMedGoogle Scholar
  111. 111.
    Gillenwater AM, Hessel AC, Morrison WH, Burgess MA, Silva EG, Roberts D, et al. Merkel cell carcinoma of the head and neck: effect of surgical excision and radiation on recurrence and survival. Arch Otolaryngol Head Neck Surg. 2001;127(2):149–54.PubMedGoogle Scholar
  112. 112.
    Jonathan RC, Michael JV, Ralph G, Christopher JOB, Patrick JG. Merkel cell carcinoma of the head and neck: is adjuvant radiotherapy necessary? Head Neck. 2007;29(3):249–57.Google Scholar
  113. 113.
    Medina-Franco H, Urist MM, Fiveash J, Heslin MJ, Bland KI, Beenken SW. Multimodality treatment of Merkel cell carcinoma: case series and literature review of 1024 cases. Ann Surg Oncol. 2001;8(3):204–8.PubMedGoogle Scholar
  114. 114.
    Eich HT, Eich D, Staar S, Mauch C, Stützer H, Groth W, et al. Role of postoperative radiotherapy in the management of Merkel cell carcinoma. Am J Clin Oncol. 2002;25(1):50–6.PubMedGoogle Scholar
  115. 115.
    Michael JV, Gary JM, Val G. Adjuvant locoregional radiotherapy as best practice in patients with Merkel cell carcinoma of the head and neck. Head Neck. 2005;27(3):208–16.Google Scholar
  116. 116.
    Esmaeli B, Naderi A, Hidaji L, Blumenschein G, Prieto VG. Merkel cell carcinoma of the eyelid with a positive sentinel node. Arch Ophthalmol. 2002;120(5):646–8.PubMedGoogle Scholar
  117. 117.
    Luir MT, Rufus M, Robert M, Thomas CC, Robert GP. Sarcomas of the head and neck. Prognostic factors and treatment strategies. Cancer. 1992;70(1):169–77.Google Scholar
  118. 118.
    William HM, Robert MB, Adam SG, Harry LE, Ang KK, Lester JP. Cutaneous angiosarcoma of the head and neck. A therapeutic dilemma. Cancer. 1995;76(2):319–27.Google Scholar
  119. 119.
    Billings SD, McKenney JK, Folpe AL, Hardacre MC, Weiss SW. Cutaneous angiosarcoma following breast-conserving surgery and radiation: an analysis of 27 cases. Am J Surg Pathol. 2004;28(6):781–8.PubMedGoogle Scholar
  120. 120.
    Mauricio G-Y. Cutaneous angiosarcoma arising on the radiation site of a congenital facial hemangioma. Int J Dermatol. 1998;37(8):638–9.Google Scholar
  121. 121.
    Lapidus CS, Sutula FC, Stadecker MJ, Vine JE, Grande DJ. Angiosarcoma of the eyelid: yellow plaques causing ptosis. J Am Acad Dermatol. 1996;34(2 Pt 1):308–10.PubMedGoogle Scholar
  122. 122.
    Ettl T, Kleinheinz J, Mehrotra R, Schwarz S, Reichert T, Driemel O. Infraorbital cutaneous angiosarcoma: a diagnostic and therapeutic dilemma. Head Face Med. 2008;4(1):18.PubMedCentralPubMedGoogle Scholar
  123. 123.
    Rosai J, Sumner HW, Kostianovsky M, Perez-Mesa C. Angiosarcoma of the skin. A clinicopathologic and fine structural study. Hum Pathol. 1976;7(1):83–109.PubMedGoogle Scholar
  124. 124.
    DeMartelaere SL, Roberts D, Burgess MA, Morrison WH, Pisters PW, Sturgis EM, et al. Neoadjuvant chemotherapy-specific and overall treatment outcomes in patients with cutaneous angiosarcoma of the face with periorbital involvement. Head Neck. 2008;30(5):639–46.PubMedGoogle Scholar
  125. 125.
    Reiser BJ, Mok A, Kukes G, Kim JW. Non-AIDS-related Kaposi sarcoma involving the tarsal conjunctiva and eyelid margin. Arch Ophthalmol. 2007;125(6):838–40.PubMedGoogle Scholar
  126. 126.
    Qureshi YA, Karp CL, Dubovy SR. Intralesional interferon alpha-2b therapy for adnexal Kaposi sarcoma. Cornea. 2009;28(8):941–3. doi:910.1097/ICO.1090b1013e3181967338.PubMedGoogle Scholar
  127. 127.
    Kirova YM, Belembaogo E, Frikha H, Haddad E, Calitchi E, Levy E, et al. Radiotherapy in the management of epidemic Kaposi’s sarcoma: a retrospective study of 643 cases. Radiother Oncol. 1998;46(1):19–22.PubMedGoogle Scholar
  128. 128.
    Vivek BP, Conway RM, Simon FT. Primary cutaneous B cell lymphoma presenting as recurrent eyelid swelling. Clin Experiment Ophthalmol. 2008;36(7):672–4.Google Scholar
  129. 129.
    Justin AG, Rodger D. Mycosis fungoides causing severe lower eyelid ulceration. Clin Experiment Ophthalmol. 2002;30(5):369–71.Google Scholar
  130. 130.
    Lker GL, SeÁil S, Erkan A, Zeliha Y, Murat DRZ. Uncommon presentation of mycosis fungoides: eyelid margin involvement. J Dermatol. 2008;35(9):581–4.Google Scholar
  131. 131.
    Fonseca Jr NL, Lucci LMD, Cha SB, Rossetti C, Rehder JRCL. Metastatic eyelid disease associated with primary breast carcinoma: case report. Arq Bras Oftalmol. 2009;72:390–3.PubMedGoogle Scholar
  132. 132.
    Douglas RS, Goldstein SM, Einhorn E, Ibarra MS, Gausas RE. Metastatic breast cancer to 4 eyelids: a clinicopathologic report. Cutis. 2002;70(5):291–5.PubMedGoogle Scholar
  133. 133.
    Yeung SN, Blicker JA, Buffam FV, Chung SW, White VA. Metastatic eyelid disease associated with hepatocellular carcinoma. Can J Ophthalmol. 2007;42(5):752–4.PubMedGoogle Scholar
  134. 134.
    Bianciotto C, Demirci H, Shields CL, Eagle Jr RC, Shields JA. Metastatic tumors to the eyelid: report of 20 cases and review of the literature. Arch Ophthalmol. 2009;127(8):999–1005.PubMedGoogle Scholar
  135. 135.
    Esmaeli B, Cleary KL, Ho L, Safar S, Prieto VG. Leiomyosarcoma of the esophagus metastatic to the eyelid: a clinicopathologic report. Ophthal Plast Reconstr Surg. 2002;18(2):159–61.PubMedGoogle Scholar
  136. 136.
    McLaughlin CC, Wu XC, Jemal A, Martin HJ, Roche LM, Chen VW. Incidence of noncutaneous melanomas in the US. Cancer. 2005;103(5):1000–7.PubMedGoogle Scholar
  137. 137.
    Shields CL, Shields JA, Gunduz K, Cater J, Mercado GV, Gross N, et al. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Arch Ophthalmol. 2000;118(11):1497–507.PubMedGoogle Scholar
  138. 138.
    Ackerman AB, Sood R, Koenig M. Primary acquired melanosis of the conjunctiva is melanoma in situ. Mod Pathol. 1991;4(2):253–63.PubMedGoogle Scholar
  139. 139.
    Folberg R, Jakobiec FA, McLean IW, Zimmerman LE. Is primary acquired melanosis of the conjunctiva equivalent to melanoma in situ? Mod Pathol. 1992;5(1):2–5. discussion 6–8.PubMedGoogle Scholar
  140. 140.
    Shields JA, Shields CL, Mashayekhi A, Marr BP, Benavides R, Thangappan A, et al. Primary acquired melanosis of the conjunctiva: experience with 311 eyes. Trans Am Ophthalmol Soc. 2007;105:61–71. discussion 71–62.PubMedCentralPubMedGoogle Scholar
  141. 141.
    Jakobiec FA, Bhat P, Colby KA. Immunohistochemical studies of conjunctival nevi and melanomas. Arch Ophthalmol. 2010;128(2):174–83.PubMedGoogle Scholar
  142. 142.
    Tuomaala S, Eskelin S, Tarkkanen A, Kivela T. Population-based assessment of clinical characteristics predicting outcome of conjunctival melanoma in whites. Invest Ophthalmol Vis Sci. 2002;43(11):3399–408.PubMedGoogle Scholar
  143. 143.
    Balch CM, Wilkerson JA, Murad TM, Soong SJ, Ingalls AL, Maddox WA. The prognostic significance of ulceration of cutaneous melanoma. Cancer. 1980;45(12):3012–7.PubMedGoogle Scholar
  144. 144.
    Savar A, Esmaeli B, Ho H, Liu S, Prieto VG. Conjunctival melanoma: localregional control rates, and impact of high-risk histologic features. J Cutan Patho. 2011;38(1):18–24.Google Scholar
  145. 145.
    Norregaard JC, Gerner N, Jensen OA, Prause JU. Malignant melanoma of the conjunctiva: occurrence and survival following surgery and radiotherapy in a Danish population. Graefes Arch Clin Exp Ophthalmol. 1996;234(9):569–72.PubMedGoogle Scholar
  146. 146.
    Kurli M, Finger PT. Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years’ experience. Graefes Arch Clin Exp Ophthalmol. 2005;243(11):1108–14.PubMedGoogle Scholar
  147. 147.
    Hsu A, Frank SJ, Ballo MT, Garden AS, Morrison WH, Rosenthal DI, et al. Post-operative adjuvant external-beam radiation therapy for cancers of the eyelid and conjunctiva. Ophthal Plast Reconstr Surg. 2008;24(6):444–9.PubMedGoogle Scholar
  148. 148.
    Ateenyi-Agaba C, Franceschi S, Wabwire-Mangen F, Arslan A, Othieno E, Binta-Kahwa J, et al. Human papillomavirus infection and squamous cell carcinoma of the conjunctiva. Br J Cancer. 2010;102(2):262–7.PubMedCentralPubMedGoogle Scholar
  149. 149.
    Guech-Ongey M, Engels EA, Goedert JJ, Biggar RJ, Mbulaiteye SM. Elevated risk for squamous cell carcinoma of the conjunctiva among adults with AIDS in the United States. Int J Cancer. 2008;122(11):2590–3.PubMedGoogle Scholar
  150. 150.
    Porges Y, Groisman GM. Prevalence of HIV with conjunctival squamous cell neoplasia in an African provincial hospital. Cornea. 2003;22(1):1–4.PubMedGoogle Scholar
  151. 151.
    Cervantes G, Rodriguez Jr AA, Leal AG. Squamous cell carcinoma of the conjunctiva: clinicopathological features in 287 cases. Can J Ophthalmol. 2002;37(1):14–9. discussion 19–20.PubMedGoogle Scholar
  152. 152.
    Mauriello Jr JA, Abdelsalam A, McLean IW. Adenoid squamous carcinoma of the conjunctiva-a clinicopathological study of 14 cases. Br J Ophthalmol. 1997;81(11):1001–5.PubMedCentralPubMedGoogle Scholar
  153. 153.
    Heindl LM, Hofmann-Rummelt C, Adler W, Holbach LM, Naumann GO, Kruse FE, et al. Tumor-associated lymphangiogenesis in the development of conjunctival squamous cell carcinoma. Ophthalmology. 2010;117(4):649–58.PubMedGoogle Scholar
  154. 154.
    Cha SB, Shields JA, Shields CL, Wang MX. Squamous cell carcinoma of the conjunctiva. Int Ophthalmol Clin. 1993;33(3):19–24.PubMedGoogle Scholar
  155. 155.
    Midena E, Angeli CD, Valenti M, de Belvis V, Boccato P. Treatment of conjunctival squamous cell carcinoma with topical 5-fluorouracil. Br J Ophthalmol. 2000;84(3):268–72.PubMedCentralPubMedGoogle Scholar
  156. 156.
    Kim JW, Abramson DH. Topical treatment options for conjunctival neoplasms. Clin Ophthalmol. 2008;2(3):503–15.PubMedCentralPubMedGoogle Scholar
  157. 157.
    Karp CL, Galor A, Chhabra S, Barnes SD, Alfonso EC. Subconjunctival/perilesional recombinant interferon alpha2b for ocular surface squamous neoplasia a 10-year review. Ophthalmology. 2010;117(12):2241–6 [epub ahead of print].PubMedGoogle Scholar
  158. 158.
    Shepler TR, Prieto VG, Diba R, Neuhaus RW, Shore JW, Esmaeli B. Expression of the epidermal growth factor receptor in conjunctival squamous cell carcinoma. Ophthal Plast Reconstr Surg. 2006;22(2):113–5.PubMedGoogle Scholar
  159. 159.
    Shields CL, Shields JA, Honavar SG, Demirci H. Primary ophthalmic rhabdomyosarcoma in 33 patients. Trans Am Ophthalmol Soc. 2001;99:133–42. discussion 142–133.PubMedCentralPubMedGoogle Scholar
  160. 160.
    Kiratli H, Shields CL, Shields JA, DePotter P. Metastatic tumours to the conjunctiva: report of 10 cases. Br J Ophthalmol. 1996;80(1):5–8.PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Head and Neck Surgery, Section of OphthalmologyThe University of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations